Search Within

David H Ilson

  1. "Biostatistics Service"
Formats
  1. Journal Article (43)
  2. Meeting Abstract (42)
  3. Miscellaneous (1)
Groups
  1. Biostatistics Service (86)
  2. Department of Medicine (86)
  3. Epidemiology and Biostatistics (86)
  4. Gastrointestinal Oncology Service (86)
  5. Solid Tumor Oncology Division (86)
  6. Center for Pancreatic Cancer Research (82)

More Groups

People
  1. Marinela Capanu (65)
  2. Yelena Janjigian (60)
  3. Geoffrey Ku (56)
  4. David Kelsen (53)
  5. Joanne Chou (36)
  6. Laura Tang (28)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (10)
  4. 2022 (6)
  5. 2021 (6)
  6. 2020 (4)

More Years

Publications
  1. Journal of Clinical Oncology (45)
  2. Annals of Surgical Oncology (5)
  3. Annals of Surgery (4)
  4. Cancer (4)
  5. Clinical Cancer Research (3)
  6. JAMA Network Open (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (45)
  2. Springer (9)
  3. American Association for Cancer Research (6)
  4. Lippincott Williams & Wilkins (5)
  5. Oxford University Press (5)
  6. Wiley Blackwell (4)

More Publishers

Results (86)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Total neoadjuvant chemo (ctx; TNT) for locally advanced gastric cancer (GC): The Memorial Sloan Kettering Cancer Center experience
    Meeting Abstract

    Greally, M.; Strong, V. E.; Yoon, S. S.; Coit, D. G.; Chou, J. F.; Capanu, M.; Kelsen, D. P.; Janjigian, Y. Y.; Ilson, D. H.; Ku, G. Y.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinical and molecular factors predicting resistance to first-line (1L) FOLFOX in patients (pts) with advanced esophagogastric cancer (EGA) and patterns of subsequent therapy
    Meeting Abstract

    Greally, M.; Walch, H. S.; Chou, J. F.; Capanu, M.; Kelsen, D. P.; Ilson, D. H.; Janjigian, Y. Y.; Schultz, N.; Ku, G. Y.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)
    Meeting Abstract

    Janjigian, Y. Y.; Chou, J. F.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Systemic chemo (CTX) plus surgery and intraperitoneal (IP) CTX for patients (pts) with gastric cancer (GC) and peritoneal carcinomatosis (PC)
    Meeting Abstract

    Greally, M.; Strong, V. E.; Yoon, S. S.; Chou, J. F.; Capanu, M.; Kelsen, D. P.; Janjigian, Y. Y.; Ilson, D. H.; Ku, G. Y.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer
    Journal Article

    Greally, M.; Chou, J. F.; Chatila, W. K.; Margolis, M.; Capanu, M.; Hechtman, J. F.; Tuvy, Y.; Kundra, R.; Daian, F.; Ladanyi, M.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Efficacy of combined VEGFR1-3, PDGFα/β, and FGFR1-3 blockade using nintedanib for esophagogastric cancer
    Journal Article

    Won, E.; Basunia, A.; Chatila, W. K.; Hechtman, J. F.; Chou, J. F.; Ku, G. Y.; Chalasani, S. B.; Boyar, M. S.; Goldberg, Z.; Desai, A. M.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer
    Journal Article

    Mondaca, S.; Margolis, M.; Sanchez-Vega, F.; Jonsson, P.; Riches, J. C.; Ku, G. Y.; Hechtman, J. F.; Tuvy, Y.; Berger, M. F.; Shah, M. A.; more...
    Gastric Cancer (2019)

    Fulltext@MSK | Save
  • EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer
    Journal Article

    Sanchez-Vega, F.; Hechtman, J. F.; Castel, P.; Ku, G. Y.; Tuvy, Y.; Won, H.; Fong, C. J.; Bouvier, N.; Nanjangud, G. J.; Soong, J.; more...
    Cancer Discovery (2019)

    Fulltext@MSK | Save
  • Phase Ib/II trial of durvalumab and chemoradiation (CRT) with carboplatin/paclitaxel for esophageal and gastroesophageal junction (GEJ) adenocarcinoma
    Meeting Abstract

    Greally, M.; Molena, D.; Sihag, S.; Wu, A. J. C.; Shah, P. M.; Fein, C.; Capanu, M.; Kelsen, D. P.; Janjigian, Y. Y.; Ilson, D. H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Genetic predictors of response to systemic therapy in esophagogastric cancer
    Journal Article

    Janjigian, Y. Y.; Sanchez-Vega, F.; Jonsson, P.; Chatila, W. K.; Hechtman, J. F.; Ku, G. Y.; Riches, J. C.; Tuvy, Y.; Kundra, R.; Bouvier, N.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save